Key Segments:
By Product
-
Ozempic
-
Trulicity
-
Mounjaro
-
Wegovy
-
Rybelsus
-
Saxenda
-
Victoza
-
Zepbound
-
Other Products
By Application
-
Type 2 Diabetes Mellitus
-
Obesity
-
Others
By Route of Administration
-
Parenteral
-
Oral
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
Others
Regional Coverage:
North America
-
US
-
Canada
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players in the North America GLP-1 Receptor Agonist Market include Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Amgen Inc., AstraZeneca plc, and Merck & Co., Inc., among others.
Key opportunities include expansion into cardiometabolic label indications, oral formulation adoption, and continued capacity investment easing supply constraints across the region.
The market is driven by rising obesity and type 2 diabetes prevalence, expanding payer coverage, and growing direct-to-consumer and telehealth prescribing access.
The Ozempic segment dominated the North America GLP-1 Receptor Agonist Market, accounting for approximately 34.10% share in 2025.
The U.S. dominated the North America GLP-1 Receptor Agonist Market in 2025 with a 90.00% share, driven by its large patient base and manufacturing concentration.
